No annual revenue total was found in PMV PHARMACEUTICALS, INC.'s SEC filings.
PMV Pharmaceuticals, Inc. (PMVP) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$73.6 million. As of Jun 30, 2026 it held $79.4 million in cash and investments and $217,000 in total debt.
Revenue
—
Net income (TTM)
$-75.22M
+7.0% vs year-ago TTM
Operating cash flow (TTM)
$-71.27M
-1.7% vs year-ago TTM
Free cash flow (TTM)
$-71.28M
-1.6% vs year-ago TTM
EPS (TTM)
$-1.41
+9.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
53.33M
+2.7% vs prior year
Net cash
$79.21M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PMVP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1699382
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$86.2M | -$85.4M | -$80.1M | -$77.0M | -$58.3M |
| Net income | -$77.7M | -$58.7M | -$69.0M | -$73.3M | -$57.8M |
| Diluted EPS | -$1.48 | -$1.14 | -$1.44 | -$1.61 | — |
| Operating cash flow | -$73.6M | -$51.3M | -$55.7M | -$63.8M | -$46.6M |
| Free cash flow | -$73.6M | -$51.9M | -$56.6M | -$71.7M | -$47.9M |
| Total assets | $116.6M | $191.3M | $252.2M | $270.3M | $331.6M |
| Total liabilities | $11.8M | $15.2M | $26.5M | $24.3M | $23.0M |
| Stockholders' equity | $104.7M | $176.1M | $225.7M | $246.0M | $308.6M |
| Cash and investments | $112.9M | $183.3M | $228.6M | $243.5M | $314.1M |
| Total debt | $838,000 | $1.2M | $13.3M | $14.0M | $11.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 5, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Sep 2, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Other events
|
Aug 31, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2026 | Jun 4, 2026 |
All 390 PMV Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.